Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481884 · ClinicalTrials.gov registry record · Phase 3
Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients
A Phase 3 study of Radiation Dermatitis, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00481884 is a Phase 3 study of Radiation Dermatitis that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, above the 34-participant average among 5 other Radiation Dermatitis trials with a reported enrollment target (135% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00481884, a Phase 3 study of Radiation Dermatitis, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To determine if RadiaPlexRx Hydrogel can reduce the development of grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation when compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care.
Conditions Studied
Interventions
- OTHER RadiaPlexRx Gel
- OTHER Aquaphor Gel
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481884
The ClinicalTrials.gov registry entry for NCT00481884 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 5 other Radiation Dermatitis trials with a reported enrollment target (135% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiation Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which RadiaPlexRx Gel is the first listed.
NCT00481884 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00481884 about?
NCT00481884 is a clinical study titled "Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients". Primary Objective: To determine if RadiaPlexRx Hydrogel can reduce the development of grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation when compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care.
What is the current status of trial NCT00481884?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2007-05. Estimated completion is 2012-01.
What conditions does trial NCT00481884 study?
This clinical trial studies the following conditions: Radiation Dermatitis.
What interventions are being tested in trial NCT00481884?
The interventions under investigation include: RadiaPlexRx Gel (OTHER), Aquaphor Gel (OTHER).
Who is sponsoring clinical trial NCT00481884?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00481884 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epidermal Skin Grafts to Improve Healing In Radiation Wounds
RECRUITING · NA
-
M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis
RECRUITING · NA
-
3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis
COMPLETED
-
Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy
COMPLETED · NA
-
Bacterial Decolonization to Prevent Radiation Dermatitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.